Search alternatives:
significantly improved » significantly increased (Expand Search)
significantly larger » significantly lower (Expand Search), significantly smaller (Expand Search), significantly higher (Expand Search)
improved decrease » improved urease (Expand Search), marked decrease (Expand Search)
larger decrease » marked decrease (Expand Search)
significantly improved » significantly increased (Expand Search)
significantly larger » significantly lower (Expand Search), significantly smaller (Expand Search), significantly higher (Expand Search)
improved decrease » improved urease (Expand Search), marked decrease (Expand Search)
larger decrease » marked decrease (Expand Search)
-
61
EF-24 treatment significantly reduces cell viability in leukemia cell lines.
Published 2025Subjects: -
62
-
63
Image 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg
Published 2025“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
-
64
Image 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg
Published 2025“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
-
65
Image 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg
Published 2025“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
-
66
Table 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.docx
Published 2025“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
-
67
Table 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx
Published 2025“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
-
68
Table 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx
Published 2025“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
-
69
Image 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg
Published 2025“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
-
70
Table 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx
Published 2025“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
-
71
Phosphorylation as an Effective Tool to Improve Stability and Reduce Toxicity of Antimicrobial Peptides
Published 2024“…Among them, W<sub>3</sub>BipY<sub>8</sub>-P stood out as the most promising peptide, exhibiting similar antibacterial activity as its unphosphorylated analog W<sub>3</sub>BipY<sub>8</sub> but with significantly reduced hemolytic activity (19-fold decrease), cytotoxicity (3.3-fold decrease), and an extended serum half-life 6.3 times longer than W<sub>3</sub>BipY<sub>8</sub>. …”
-
72
Significant associations in GWAS.
Published 2025“…<div><p>Decreased nitric oxide (NO) production from the vascular endothelium is a major factor for vascular aging. …”
-
73
-
74
-
75
BT9 did not improve survival in the orthotopic xenograft model of D425 medulloblastoma.
Published 2024Subjects: -
76
-
77
-
78
-
79
-
80